Attached files

file filename
EX-31 - SANGUI BIOTECH INTERNATIONAL INCf20180331_exhibit31.02vedgar.htm
EX-31 - SANGUI BIOTECH INTERNATIONAL INCf20180331_exhibit31.01vedgar.htm
10-Q - SANGUI BIOTECH INTERNATIONAL INCsangui10q_20180331_audit_201.htm


Exhibit 32.01


CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Sangui Biotech International, Inc. (the Company) on Form 10-Q for the period ending March 31, 2018 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, Thomas Striepe, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief:

 

(1)

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

 

(2)

The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.



 

Dated: May 03, 2018

/s/ Thomas Striepe                                              

By: Thomas Striepe

Chief Executive Officer and

Chief Financial Officer

  

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.